Searchable abstracts of presentations at key conferences in endocrinology

ea0063p437 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Hypoadrenalism in Advanced HIV

Ross Ian , Millar Robert , Mofokeng Thabiso , Grossman Ashley , Dave Joel , Levitt Naomi , Pillay Tahir , Erasmus Rajiv , Raubenheimer Peter , Dandara Collet , Johannsson Gudmundur

Background: Large populations of HIV and tuberculosis occur in South Africa and, amongst these patients, Addison’s disease is probably underdiagnosed. Preliminary data in 60 HIV-positive patients with a CD4 count less than 100 cells/mm3 showed that the overall prevalence of hypoadrenalism was 6.7%, with 1 patient having primary hypoadrenalism and 3 patients having central hypoadrenalism. This report describes the prevalence of hypoadrenalism and its association...

ea0044p78 | Clinical biochemistry | SFEBES2016

Management of multiple endocrine neoplasia type 1 (MEN1) and sporadic pancreatic neuroendocrine tumours (PNETS) in relation to the clinical guidelines: a single centre audit

Ntali Georgia , Newey Paul J , Stokes Victoria , Talbot Denis , Soonawalla Zahir , Sadler Greg , Karavitaki Niki , Grossman Ashley B , Thakker Rajesh V

Introduction and aim: Pancreatic neuroendocrine tumours (PNETs) may occur sporadically (sPNETs) or as part of the multiple endocrine neoplasia type 1(MEN1) syndrome, which is characterised by occurrence of PNETs, parathyroid and anterior pituitary tumours. Our aim was to review the management of these patients in relation to the clinical practice MEN1 guidelines, and the ENETS and UKINETS guidelines for PNETs.Patients and methods: Patients attending with...

ea0035p586 | Endocrine tumours and neoplasia | ECE2014

The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells

Dworakowska Dorota , Dudka Dorota , Weistman Gregory , King Peter , Diaz-Cano Salvador , Korbonits Marta , Grossman Ashley B , Aylwin Simon , Schulte Klaus-Martin , Sworczak Krzysztof , Ng Tony

Introduction: Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered as a first-line therapy but only 30% of the patients showing an objective tumour response.Erlotinib and gefitinib (tyrosine kinase inhibitors – TKI) inhibit the epidermal growth factor receptor (EGFR), which is highly expressed and occasionally mutated in various cancers. EGFR expression was found to be a good ...

ea0060p24 | (1) | UKINETS2018

Assessment of fat-soluble vitamins and trace elements in neuroendocrine tumour (NET) patients on somatostatin analogues

Ewang-Emukowhate Mfon , Whyand Tara , Chotai De Lima Yasmin , Toumpanakis Christos , Mandair Dalvinder , Hayes Aimee , Grossman Ashley , Nair Devaki , Caplin Martyn

Introduction: NETs are a diverse group of neoplasms that originate from cells of the diffuse endocrine system. Often somatostatin analogues (SSA) are used as a first line treatment. Loose stools and steatorrhea are common adverse effects of SSA. This can affect the absorption of fat soluble vitamins and trace elements (TE). In this study we assess the prevalence of these deficiencies.Methods: A prospective study of 66 patients on SSA. Vitamins A,D,E,K an...

ea0058oc5.5 | Oral Communications 5 | BSPED2018

New insights into the low dose dexamethasone suppression test in paediatric Cushing’s syndrome (CS)

Wilkinson Ingrid CE , Riddoch Fiona , Perry Lesley A , Martin Lee , Grossman Ashley B , Monson John P , Akker Scott , Savage Martin O , Drake William M , Storr Helen L

Background: The low dose dexamethasone suppression test (LDDST) is an important investigation for suspected Cushing’s syndrome (CS). The traditional definition of normal suppression of serum cortisol to ≤50 nmol/l (0.5 mg 6 hrly × 48 hrs) comes from a time when biochemical auto analysers did not routinely detect very low values. Previous studies reported 5.1–8.3% of patients with Cushing’s disease (CD) suppressed to <50 nmol/l at 48 hrs. Many clin...

ea0070oc7.2 | Endocrine-related Cancer | ECE2020

The role of the tumour microenvironment in pituitary adenoma angiogenesis

Marques Pedro , Barry Sayka , Carlsen Eivind , Collier David , Ronaldson Amy , Awad Sherine , Mendoza Nigel , Muquit Samiul , Dorward Neil , Grieve Joan , Balkwill Frances , Grossman Ashley B , Korbonits Marta

Introduction: Angiogenesis is regulated by different components of the tumour microenvironment (TME) including cytokines and immune cells. Although angiogenesis has been studied in pituitary adenomas (PAs), the role of individual TME components in PA angiogenesis remains largely unknown. We aimed to characterise the role of the TME components in determining the angiogenesis of PAs, focusing on PA-infiltrating immune cells and the PA-derived cytokine network.<p class="abste...

ea0031p258 | Pituitary | SFEBES2013

Prevalence of familial isolated pituitary adenomas

Herincs M , Owusu-Antwi S , Chahal H S , Kumar S R , Ozfirat Z , Grossman A B , Druce M R , Akker S A , Drake W M , Korbonits M

While pituitary adenomas (PA) usually occur as a sporadic disease, an increasing number of patients are recognised with a family member also suffering from a PA. If no other syndromic features are present, these families are categorised as FIPA. In published studies, 20% of the FIPA families, 20% of sporadic childhood and 13% of sporadic young-onset (≤30 years) acromegaly patients carry a germline AIP mutation. As familial disease is more aggressive, family scre...

ea0028p236 | Pituitary | SFEBES2012

Evaluation of the expression of vesicular protein (SNARE) isoforms in human pituitary adenomas

Garcia Edwin , Trivellin Giampaolo , Michael Powell , Grieve Joan , Sabin Ian , Alusi Ghassan , Louis Pobereskin , Shariati Babak , Roncaroli Federico , Mendoza Nigel , Grossman Ashley , Harper Elaine , Korbonits Marta

Background: Botulinum neurotoxin inhibits muscle function by interfering with neurotransmitter release from secretory vesicles. The mechanism underlying this effect involves cleavage of SNARE proteins which are required for vesicle docking at the plasma membrane. The ability of botulinum neurotoxin serotypes to cleave SNARE proteins and inhibit secretion is being exploited for therapeutic purposes by Syntaxin Ltd with their ‘targeted secretion inhibitor technology’ (...

ea0021oc2.4 | Neuroendocrine tumours/pituitary | SFEBES2009

Geographical cluster of familial isolated pituitary adenoma kindreds with an identical AIP mutation

Ozfirat Zehra , Cain Josh , Chahal Harvinder , Stals Karen , Ellard Sian , Howlett Trevor , Levy Miles , Atkinson Brew , Morrison Patrick , Akker Scott , Grossman Ashley , Korbonits Marta

Mutations in the co-chaperone molecule AIP account for a predisposition to pituitary tumours in some families with familial isolated pituitary adenomas (FIPA). We now report on four apparently-unrelated families with the same mutation and originating from the same geographical area, suggesting a possible founder mutation.The index patient had gigantism (19 years, 208 cm) and had a female 4th cousin, once removed (13 years, 191 cm) with a large pituitary ...

ea0021p285 | Pituitary | SFEBES2009

Electrocardiographic features in Cushing’s disease: are there specific EKG changes associated with hypercortisolemia?

Alexandraki Krystallenia , Kaltsas Gregory , Vouliotis Apostolos , Papaioannou Theodoros , Apostolopoulos Nikolaos , Trisk Lauren , Zilos Athanasios , Akker Scott , Chew Shern , Drake William , Anastasakis Aris , Grossman Ashley

Introduction: Hypercortisolaemia is characterised by an increased risk of cardiovascular disease (CVD), either through a direct action on the myocardium or by affecting traditional cardiovascular risk factors. The electrocardiogram (ECG) is the initial examination to assess the structural and functional characteristics of the myocardium.Aim of the study: To investigate whether the metabolic and cardiovascular features of Cushing’s disease (CD) are a...